H2 Blocker

DRUG2 trials

Sponsors

Prolacta Bioscience, Ultragenyx Pharmaceutical Inc

Conditions

Glycogen Storage Disease Type IIIHealthy Adult Subjects

Phase 1

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

TerminatedNCT04990388

Ultragenyx Pharmaceutical IncGlycogen Storage Disease Type III

Start: 2021-10-18End: 2023-03-20Updated: 2024-04-16

Unknown Phase

Dietary Supplement With and Without a Probiotic

CompletedNCT04433208

Prolacta BioscienceHealthy Adult Subjects

Start: 2020-03-13End: 2020-12-02Updated: 2025-03-18